BioCentury | Aug 13, 2020
Finance

After biggest STAR listing yet for a biotech, vaccine developer CanSino posts big gain

Demand for CanSino’s shares ran high in the company’s first day of trading on Shanghai’s STAR exchange, lifting the company’s market cap to about RMB97 billion ($14 billion) at market close after briefly rising as high...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

BIO is calling on biopharmaceutical companies to put their pledges on social justice into practice as the trade group launches an initiative that aims to diversify the biotech workforce and ensure that clinical trials reflect...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Aug 5, 2020
Product Development

Novavax COVID-19 vaccine potently immunogenic with room to lower dose

Although prime-boost administration of the likely Phase II dose of Novavax’s COVID-19 vaccine led to severe adverse events in a small proportion of Phase I volunteers, the human immunogenicity and baboon protection data suggest there’s...
BioCentury | Jul 31, 2020
Product Development

Can the vogue of decentralized trials continue beyond the pandemic?

Decentralizing clinical trials has become a must-do rather than nice-to-have during the pandemic, with hospital shutdowns and restricted access disrupting company programs and putting enrolled patients at risk. But a range of logistical challenges need...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

Two more COVID vaccine developers have published non-human primate data suggesting efficacy, bringing the total to five. One of the new papers builds on the case for neutralizing antibodies as key correlates of protection; the...
BioCentury | Jul 30, 2020
Deals

F-Star lands on NASDAQ sooner than expected via reverse merger

At the year’s start F-Star Therapeutics’ plan was to ride out the expected volatility of the U.S. election year and seek a public listing in 2021. That changed when Spring Bank called with an opportunity...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine. Shares of TCR...
Items per page:
1 - 10 of 13724